Literature DB >> 18067920

Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging.

Tao Wang1, Chunjuan Tian, Wenyan Zhang, Phuong Thi Nguyen Sarkis, Xiao-Fang Yu.   

Abstract

Human cytidine deaminase apolipoprotein B mRNA-editing catalytic polypeptide-like 3F (APOBEC3F, or A3F), like APOBEC3G, has broad antiviral activity against diverse retroelements, including Vif-deficient human immunodeficiency virus (HIV)-1. Its antiviral functions are known to rely on its virion encapsidation and be suppressed by HIV-1 Vif, which recruits Cullin5-based E3 ubiquitin ligases. However, the factors that mediate A3F virion packaging have not yet been identified. In this study, we demonstrate that A3F specifically interacts with cellular signal recognition particle (SRP) RNA (7SL RNA), which is selectively packaged into HIV-1 virions. Efficient packaging of 7SL RNA as well as A3F was mediated by the RNA-binding nucleocapsid domain of HIV-1 Gag. Reducing 7SL RNA packaging by overexpression of SRP19 protein inhibited A3F virion packaging. Although A3F has been shown to interact with P bodies and viral genomic RNA, our data indicated that P bodies and HIV-1 genomic RNA were not required for A3F packaging. Thus, in addition to its well-known function in SRPs, 7SL RNA, which is encapsidated into diverse retroviruses, also participates in the innate antiviral function of host cytidine deaminases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18067920     DOI: 10.1016/j.jmb.2007.11.017

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  48 in total

1.  Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity.

Authors:  Xiaojun Wang; Aierken Abudu; Sungmo Son; Ying Dang; Patrick J Venta; Yong-Hui Zheng
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

2.  The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity.

Authors:  Marcel Ooms; Susan Majdak; Christopher W Seibert; Ariana Harari; Viviana Simon
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

3.  7SL RNA is retained in HIV-1 minimal virus-like particles as an S-domain fragment.

Authors:  Sarra E Keene; Steven R King; Alice Telesnitsky
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

Review 4.  Functions and regulation of the APOBEC family of proteins.

Authors:  Harold C Smith; Ryan P Bennett; Ayse Kizilyer; William M McDougall; Kimberly M Prohaska
Journal:  Semin Cell Dev Biol       Date:  2011-10-06       Impact factor: 7.727

5.  cis-Acting determinants of 7SL RNA packaging by HIV-1.

Authors:  Sarra E Keene; Alice Telesnitsky
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

Review 6.  Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Authors:  Belete A Desimmie; Krista A Delviks-Frankenberrry; Ryan C Burdick; DongFei Qi; Taisuke Izumi; Vinay K Pathak
Journal:  J Mol Biol       Date:  2013-11-02       Impact factor: 5.469

7.  Biochemical and biological studies of mouse APOBEC3.

Authors:  Smita Nair; Silvia Sanchez-Martinez; Xinhua Ji; Alan Rein
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103

Review 8.  APOBECs and virus restriction.

Authors:  Reuben S Harris; Jaquelin P Dudley
Journal:  Virology       Date:  2015-03-26       Impact factor: 3.616

9.  The in vitro Biochemical Characterization of an HIV-1 Restriction Factor APOBEC3F: Importance of Loop 7 on Both CD1 and CD2 for DNA Binding and Deamination.

Authors:  Qihan Chen; Xiao Xiao; Aaron Wolfe; Xiaojiang S Chen
Journal:  J Mol Biol       Date:  2016-04-08       Impact factor: 5.469

10.  APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells.

Authors:  Jinhui Li; Yan Chen; Ming Li; Michael A Carpenter; Rebecca M McDougle; Elizabeth M Luengas; Patrick J Macdonald; Reuben S Harris; Joachim D Mueller
Journal:  J Mol Biol       Date:  2013-12-17       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.